There has been interest in developing pharmacologic inhibitors of MEK as a means to blocking ERK activation in tumours with activating mutations of MEK1 or MEK2 such as ovarian, melanoma, colorectal and lung cancer [10]. Here, MAP2K7 is linked to lung cancer.